Bicoll GmbH
About us
Advancing Drug Discovery with Precision and Speed
Bicoll is a pioneering biopharmaceutical company specializing in high-tech natural product chemistry and medicinal chemistry to drive innovation in drug discovery. We identify novel small molecules with high therapeutic potential, supporting preclinical research through naturally derived plant compounds and advanced chemical synthesis.
Why Partner with Bicoll?
1. Expertise in Challenging Targets – We specialize in targeting difficult-to-treat conditions, unlocking new therapeutic possibilities.
2. Broad Pharmaceutical Applications – Our research spans multiple indications, ensuring versatile solutions for diverse medical needs.
3. Proven Success in Agriculture – With a strong track record in pesticides, insecticides, and crop protection, we extend our expertise beyond human health.
4. Rapid Compound Delivery – We provide single-compound structures of interest with a full project timeline of just 3 months.
5. Accelerated Drug Discovery – From initial screening to animal testing, we streamline the process within an industry-leading 9-month timeframe.
Our solutions extend beyond pharmaceuticals, bringing cutting-edge innovation to cosmetics, nutraceuticals, and agriculture. With our unique blend of scientific expertise and efficiency, we empower partners with research-driven breakthroughs that redefine the future of healthcare and beyond.
Let’s collaborate! Contact us today to accelerate your next discovery.
Address
Am Klopferspitz 19
82152 Planegg
Germany
E-mail: contact@bicoll-group.com
Phone: +49 898 2010630
Internet: bicoll-group.com/
Contact person:
Maria Lamottke
E-mail: contact@bicoll-group.com
Products & Services
1. Medicinal Chemistry
Bicoll uses state-of-the-art chemistry to accelerate its own drug discovery programs. It includes a broad range of target classes, parallel synthesis capabilities, custom synthesis from microgram to multiple hundred grams of biologically active compounds as well as pre-clinical scale-up capabilities. Unique natural product approaches are combined with subsequent medicinal chemistry programs and a 25-year-long proven track record.
2. Natural Product Libraries
Bicoll has been working with plant secondary metabolites for over 20 years. Starting with fractions it could overcome existing problems while working with extracts. Bicoll focuses on finding single active compounds in plants, which is a relevant starting point (compounds) for research programs in the nutraceutical, pharmaceutical, and agriculture industries. Plant ProfilesTM (fine fractions library) is in general DMSO-soluble. Technology implies the separation of the starting points (crude extracts) into polar and non-polar parts.
3. Current developments/products
Bicoll has developed the following own products for partnerships:
a) Set of taste modeling and bitter masking substances for nutraceutical and food development (patented)
b) Preclinical neurologically active small molecule (see 4NEURON www.4neuron.com)
c) Anti-inflammatory small molecules (repurposing)
4NEURON: New chemical class of small molecules
We have meticulously designed and developed a pioneering class of compounds that set new standards in epilepsy treatment. These compounds boast unparalleled efficacy, a remarkable safety profile, and the potential to redefine patient compliance.
Game-Changing Results: Our flagship small molecule, the result of years of dedication and scientific rigor, has unveiled a groundbreaking breakthrough. In acute viable brain slices from multi drug-resistant human epilepsy patients, it has demonstrated exceptional anti-seizure efficacy and an extraordinary reduction in side effects compared to existing therapies, offering a glimmer of hope in epilepsy management like never before.
Taste modelling compounds
Patented new set of small molecules for nutraceutical and food industry:
2017 Taste modulating flavoring substances PCT/EP2017/065457 – WO2018233841 (A1)
2021 Dihydrochalcone Derivatives: Enhancing Flavor as Sweet Tasting and Sweet Modulating Agents WO2023065059A1
further patents not disclosed yet
Repurposing Adapalene as a glucocorticoid receptor modulator to treat inflammatory diseases
2024 US2024074997A1 Repurposing Adapalene as a glucocorticoid receptor modulator to treat inflammatory diseases
A method of treating an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a glucocorticoid receptor modulator comprising a therapeutically acceptable salt, solvate, or stereoisomer thereof of Adapalene as well as pharmaceutical compositions comprising Adapalene for the management of these inflammatory diseases.
